Roivant Sciences ROIV Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $3.35M-76.2% | $14.07M-36.1% | $22.04M+16.9% | $18.86M— | ||
| $178.11M-31.1% | $258.38M+76.5% | $146.43M— | —— | ||
| $4.01M+137% | -$10.72M-74.6% | -$6.14M-1,164% | -$486K-115% | ||
| —— | $55.19M— | —— | —— | ||
| —— | -$171.98M-104% | $4.5B+546% | -$1.01B-19.4% | ||
| $1.29M+41.1% | $911K-81.1% | $4.83M— | —— | ||
| $3.77M— | —— | —— | $6.28M— | ||
| $0-100% | $774K-50.0% | $1.55M+124% | $692K— | ||
| $0-100% | $110.39M-97.9% | $5.35B— | —— | ||
| $3.42M— | —— | —— | —— | ||
| —— | —— | $40.15M+3.1% | $38.96M-23.0% | ||
| -$2.39M+58.2% | -$5.7M+31.5% | -$8.33M+3.2% | -$8.6M— | ||
| -$11.46M— | —— | $88.99M+181% | $31.67M— | ||
| —— | —— | —— | —— | ||
| $770.24M— | $0— | $0— | —— | ||
| —— | -$1.22B-370% | $451.99M-10.8% | $506.8M+60.8% | ||
| —— | —— | $5.2B— | —— | ||
| -$750.35M+10.6% | -$839.45M-9.7% | -$765.27M+9.3% | -$843.39M-24.4% | ||
| $8.28M+20.9% | $6.84M0.0% | $6.85M-9.5% | $7.57M— | ||
| —— | -$3.76M+63.3% | -$10.25M-148% | $21.21M— | ||
| —— | $1.29B— | $0— | $0— | ||
| —— | $4.6M+233% | $1.38M-89.1% | $12.69M-27.2% | ||
| $268.35M+441% | $49.6M-8.7% | $54.31M+1,830% | $2.81M+583% | ||
| $346.17M+19.8% | $289.03M+44.8% | $199.63M-8.3% | $217.78M-61.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Roivant Sciences's revenue?
- Roivant Sciences (ROIV) generated $8.3M in revenue over the trailing twelve months, down 71.6% year over year.
- Where does Roivant Sciences's income statement data come from?
- Every line is extracted from Roivant Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
